Image: The MCED test can detect up to 42 solid tumors and five hematological tumors (photo courtesy of 123RF)
Cancer is responsible for almost 1 in 6 deaths worldwide. Each year, more than 14 million people are diagnosed with cancer, and this number is expected to exceed 21 million by 2030. A major problem is that many cases of cancer are detected too late. Approximately 70% of all cancer-related deaths come from cancers for which there are no established screening tests, and they are often diagnosed at an advanced stage. Even in countries with highly developed healthcare systems, a significant number of cancers are identified at a late stage, when successful treatment is more difficult. There is a pressing need for innovative, non-invasive screening tests to detect cancer in asymptomatic people, particularly during the early stages when treatment is most effective. A new multiple cancer early detection (MCED) test, using routine blood and urine samples and powered by a machine learning (ML) algorithm, now offers the ability to detect up to 42 solid tumors and five hematological tumors.
Developed by Kience Inc. (Wilmington, DE, USA), the Venient Sx MCED test can accurately detect 42 types of solid tumors and 5 hematologic tumors, which together account for 95.2% of all new cancer cases worldwide . It is able to identify cancer in early stages, even before symptoms appear, allowing for more successful treatment. Additionally, the test detects up to 276 non-malignant diseases related to major body functions, systems and overall metabolism, many of which are known risk factors for cancer.
The Venient Sx MCED test provides information about the possible onset of diseases years in advance by analyzing clinical data, laboratory results and lifestyle factors. The comprehensive, personalized report generated by the test suggests preventive measures to address both non-malignant diseases and potential cancer risks, helping to prevent its natural progression. Studies validating the Venient Sx MCED test have shown that it achieves 95% sensitivity, 73% specificity, and 95% accuracy in 276 non-malignant conditions. The Venient Sx MCED test has already obtained the CE mark and is currently undergoing certification in the United States.
Related links:
Kience Inc.
